Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Suriname Healthcare Press.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on June 20, 2025
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
GlobeNewswire
·
June 20, 2025
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 20, 2025
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of …
The Ensign Group, Inc. Announces Retirement of Its Executive Chairman
GlobeNewswire
·
June 20, 2025
SAN JUAN CAPISTRANO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG or “Ensign”), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, …
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 20, 2025
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for …
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
GlobeNewswire
·
June 20, 2025
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced …
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GlobeNewswire
·
June 20, 2025
BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a …
PharmAla Files Preliminary Base Shelf Prospectus
GlobeNewswire
·
June 20, 2025
TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its …
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
GlobeNewswire
·
June 20, 2025
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the …
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
GlobeNewswire
·
June 20, 2025
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a “Questions and …
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché
GlobeNewswire
·
June 20, 2025
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché NANTES, France, 20 juin 2025, 19 heures 30 – OSE Immunotherapeutics SA (ISIN: FR0012127173; …
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
GlobeNewswire
·
June 20, 2025
DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, …
SanMelix announces the addition of Mr. Ajay Dhaul to our Board of Directors and Executive Leadership team in the role of Chief Strategy & Growth Officer
GlobeNewswire
·
June 20, 2025
Poinciana, Fl, June 20, 2025 (GLOBE NEWSWIRE) -- SanMelix, the company behind BeeCure Radiation Burn Relief Cream, is excited to announce the addition of Mr. Ajay Dhaul to our Board of Directors and Executive Leadership team in the role of Chief Strategy …
Rakovina Therapeutics Announces Share Consolidation Effective Date
GlobeNewswire
·
June 20, 2025
VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “ …
Dr. Myung Ju Lee Shared Enhanced Deep-Plane Facelift Technique at ISAPS Olympiad World Congress
GlobeNewswire
·
June 20, 2025
JEJU, South Korea, June 20, 2025 (GLOBE NEWSWIRE) -- Dr. Myung Ju Lee, MD, PhD, Chief Surgeon at VIP Plastic Surgery Clinic in Jeju, South Korea, a leading Korean plastic surgery clinic, presented groundbreaking research on facelift innovation at the …
Moleculin Announces $5.9 Million Public Offering
GlobeNewswire
·
June 20, 2025
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the …
INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time
GlobeNewswire
·
June 20, 2025
SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility focused company, reminds shareholders to vote their shares online ahead of the upcoming annual meeting of …
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
GlobeNewswire
·
June 20, 2025
CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult- …
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
GlobeNewswire
·
June 20, 2025
SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and …
Safety Shot Provides Update on Expected Closing of Yerbaé Brands Corp. Acquisition
GlobeNewswire
·
June 20, 2025
SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided an update on the expected timing for the closing of its previously announced acquisition of Yerbaé Brands Corp. (TSX-V: YERB. …
Emergent BioSolutions Announces Addition to Russell 3000® Index
GlobeNewswire
·
June 20, 2025
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual …